Drug intelligence / Profile preview

HWO-001

Development stage: Preclinical
Lead developer: Hanwha Pharma
Modality: Small Molecules

Overview

HWO-001 is a preclinical-stage drug candidate being developed by Han Wha Pharma (Hanwha Pharma) for the treatment of cardiovascular and endocrine disorders. As a "New Drug" project within the company's R&D pipeline, it is likely a synthetic small molecule, consistent with Han Wha Pharma's focus on synthetic drug discovery. Specific details regarding its biological target, mechanism of action, and exact indications within the cardiovascular and endocrine therapeutic areas have not yet been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on HWO-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HWO-001.

Explore the full profile